Viewing Study NCT01134666


Ignite Creation Date: 2025-12-24 @ 4:25 PM
Ignite Modification Date: 2026-03-27 @ 7:03 PM
Study NCT ID: NCT01134666
Status: TERMINATED
Last Update Posted: 2017-06-09
First Post: 2010-05-28
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer
Sponsor: Merck KGaA, Darmstadt, Germany
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Colorectal Neoplasms View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Colorectal neoplasms View
None Intestinal neoplasms View
None Neoplasms View
None cetuximab View
None Erbitux View